Daix (France), New York City (New York, United States), July 2, 2026 -- Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the results of the votes of its Combined Shareholders' Meeting.
The Combined Shareholders' Meeting was held on Tuesday June 30, 2026, at 2 p.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Andrew Obenshain, Chief Executive Officer of Inventiva.
Mr. Andrew Obenshain proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mrs Susan Coles and Mr. Jean Volatier, as tellers, as well as Mr. Abel Colomb, as secretary of the general meeting.
All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 31(st) resolution, which had been the subject of a negative recommendation by the Board of Directors. The 31(st) resolution would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.
Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders' Meeting approved, without modification, the compensation policy for corporate officers as presented in the 2025 Universal Registration Document (section 3.5.1, pages 134 et seq.) and, with respect specifically to the chairman of the board of directors, in the notice of meeting (brochure de convocation) for the Combined General Meeting, made available on the Company's website under the "General Meetings" section.
The results of the vote are presented below:
-- Total number of shares composing the share capital: 236 280 202
-- Total number of shares with voting rights: 236 280 202
ORDINARY PART EXTRAORDINARY PART
------------------------------------ ------------------------------------
Shareholders Shares Votes Shareholders Shares Votes
------------- ------------ ---------- ---------- ------------ ---------- ----------
Shareholders
Present 5 318 490 519 790 5 318 490 519 790
------------- ------------ ---------- ---------- ------------ ---------- ----------
Proxy To
Third
Parties 0 0 0 0 0 0
------------- ------------ ---------- ---------- ------------ ---------- ----------
Proxy To
The Chairman 214 21 380 077 21 505 444 214 21 380 077 21 505 444
------------- ------------ ---------- ---------- ------------ ---------- ----------
148 125 155 342 148 125 155 342
Mail Votes 221 573 788 221 573 788
------------- ------------ ---------- ---------- ------------ ---------- ----------
169 824 177 368 169 824 177 368
TOTAL 440 140 022 440 140 022
QUORUM 71,874 % 71,874 %
------------- ------------------------------------ ------------------------------------
VOTE RESULTS: Ordinary Resolutions
Total Total
votes number Proportion of
taken of represented Non-
into votes share voting Invalid
Resolution Results For Against Abstention account cast capital votes votes Quorum
---------- ------- ------- ------ ------------- ------ ------- --------
Votes % Votes % Votes %
---------- ------- ----- ----- ------- ----- ------ ------ ------- ------ ----------- ------ ------- ------
177
222 99,92 0,08 177 355 169 824 71,874
1 Adopted 228 % 133 103 % 12 691 - 331 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
177
221 99,92 0,08 177 355 169 824 71,874
2 Adopted 334 % 134 197 % 12 491 - 531 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
177
221 99,92 0,08 177 355 169 824 71,874
3 Adopted 057 % 134 109 % 12 856 - 166 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
177
218 99,92 0,08 177 357 169 824 71,874
4 Adopted 663 % 138 566 % 10 793 - 229 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
169
001 99,80 0,20 169 335 161 799 8 024 71,874
5 Adopted 759 % 333 429 % 8 475 - 188 781 68,477 % 359 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
142
101 80,13 35 235 19,87 177 337 169 824 71,874
6 Adopted 931 % 606 % 30 485 - 537 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
142
260 80,22 35 075 19,78 177 336 169 824 71,874
7 Adopted 329 % 808 % 31 885 - 137 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
142
242 80,21 35 094 19,79 177 336 169 824 71,874
8 Adopted 043 % 119 % 31 860 - 162 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
142
260 80,22 35 075 19,78 177 336 169 824 71,874
9 Adopted 377 % 785 % 31 860 - 162 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
171
116 96,49 6 233 3,51 177 349 169 824 71,874
10 Adopted 568 % 151 % 18 303 - 719 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
142
115 80,14 35 219 19,86 177 335 169 824 71,874
11 Adopted 577 % 585 % 32 860 - 162 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
142
256 80,22 35 077 19,78 177 334 169 824 71,874
12 Adopted 741 % 573 % 33 708 - 314 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
403 80,86 33 943 19,14 177 346 169 824 71,874
13 Adopted 465 % 220 % 21 337 - 685 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
170
745 96,28 6 604 3,72 177 350 169 824 71,874
14 Adopted 845 % 810 % 17 367 - 655 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
172
576 97,31 4 763 2,69 177 339 169 824 71,874
15 Adopted 402 % 296 % 28 324 - 698 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
174
294 98,28 3 044 1,72 177 339 169 824 71,874
16 Adopted 992 % 831 % 28 199 - 823 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
151
354 85,35 25 987 14,65 177 341 169 824 71,874
17 Adopted 591 % 080 % 26 351 - 671 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
151
353 85,35 25 987 14,65 177 341 169 824 71,874
18 Adopted 927 % 714 % 26 381 - 641 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
151
170 85,24 26 170 14,76 177 341 169 824 71,874
19 Adopted 758 % 883 % 26 381 - 641 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
145
764 82,20 31 566 17,80 177 330 169 824 71,874
20 Adopted 550 % 386 % 37 086 - 936 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
177
215 99,93 0,07 177 342 169 824 71,874
40 Adopted 321 % 127 471 % 25 230 - 792 140 71,874 % 0 0 %
---------- ------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
VOTE RESULTS: Extraordinary Resolutions
Total Total
votes number Proportion of
taken of represented Non-
into votes share voting Invalid
Resolution Results For Against Abstention account cast capital votes votes Quorum
---------- -------- ------- ------ ------------- ------ ------- --------
Votes % Votes % Votes %
---------- -------- ----- ----- ------- ----- ------ ------ ------- ------ ----------- ------ ------- ------
175
557 98,99 1 790 1,01 177 347 169 824 71,874
21 Adopted 047 % 590 % 20 385 - 637 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
144
164 81,28 33 194 18,72 177 358 169 824 71,874
22 Adopted 252 % 352 % 9 418 - 604 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
103 80,69 34 255 19,31 177 358 169 824 71,874
23 Adopted 408 % 067 % 9 547 - 475 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
083 80,68 34 256 19,32 177 340 169 824 71,874
24 Adopted 973 % 866 % 27 183 - 839 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
090 80,69 34 253 19,31 177 343 169 824 71,874
25 Adopted 257 % 657 % 24 108 - 914 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
086 80,68 34 257 19,32 177 343 169 824 71,874
26 Adopted 234 % 680 % 24 108 - 914 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
090 80,69 34 251 19,31 177 341 169 824 71,874
27 Adopted 519 % 194 % 26 309 - 713 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
260 80,77 34 099 19,23 177 359 169 824 71,874
28 Adopted 260 % 506 % 8 256 - 766 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
162 80,73 34 180 19,27 177 343 169 824 71,874
29 Adopted 737 % 406 % 24 879 - 143 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
245 80,77 34 096 19,23 177 341 169 824 71,874
30 Adopted 142 % 744 % 26 136 - 886 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
81
472 45,94 95 870 54,06 177 342 169 824 71,874
31 Rejected 089 % 777 % 25 156 - 866 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
177
054 99,83 0,17 177 361 169 824 71,874
32 Adopted 574 % 307 309 % 6 139 - 883 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
142
122 80,13 35 237 19,87 177 359 169 824 71,874
33 Adopted 037 % 007 % 8 978 - 044 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
142
066 80,10 35 284 19,90 177 351 169 824 71,874
34 Adopted 660 % 507 % 16 855 - 167 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
260 80,78 34 095 19,22 177 356 169 824 71,874
35 Adopted 220 % 970 % 11 832 - 190 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
177
186 99,91 0,09 177 339 169 824 71,874
36 Adopted 176 % 153 411 % 28 435 - 587 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
177
211 99,93 0,07 177 344 169 824 71,874
37 Adopted 214 % 132 881 % 23 927 - 095 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
381 80,85 33 961 19,15 177 343 169 824 71,874
38 Adopted 185 % 896 % 24 941 - 081 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
143
934 81,16 33 415 18,84 177 350 169 824 71,874
39 Adopted 896 % 428 % 17 698 - 324 140 71,874 % 0 0 %
---------- -------- ----- ----- ------- ----- -------- ---- ------- -------- ----------- ------ --------- ------
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://www.inventivapharma.com
Contacts
Media Relations Pascaline Clerc: Investor Relations David Nikodem: media@inventivapharma.com Mark Corbae: IR@inventivapharma.com Patricia L. inventivapr@icrhealthcare.com Bank: patti.bank@icrhealthcare.com
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates regarding Inventiva's cash resources and expenses, forecasts and estimates with respect to Inventiva's NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH, including the quality of trial results, design, duration, timing, costs, and funding, timing of clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva's pipeline and development plans, and Inventiva's future activities, expectations, plans, growth and prospects. Some of these statements, forecasts, and estimates may be identified by the use of words such as, without limitation, "believe," "anticipate," "expect," "intend," "plan," "seek," "estimate," "may," "will," "could," "should," "designed," "hope," "target," "potential," "opportunity," "possible," "aim," and "continue" and other similar expressions. These statements are not historical facts, but rather statements of future expectations and other forward-looking statements based on management's beliefs. These statements reflect the opinions and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend on factors beyond Inventiva's control. There can be no guarantee, with respect to product candidates, that clinical trial results will be available on schedule, that future clinical trials will be initiated as planned, that product candidates will receive the necessary regulatory approvals, or that the milestones planned by Inventiva or its partners will be achieved on schedule, or even at all. Future results may differ materially from the anticipated future results, performance, or achievements expressed or implied by these statements, forecasts, and estimates due to a number of factors, including the fact that interim data or data from any interim analysis of ongoing clinical trials do not predict the future results of clinical trials, the fact that the DMC's recommendation does not prejudge any eventual marketing authorization, that Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on recruitment or the final impact on the results or timing of the NATiV3 trial or related regulatory issues, Inventiva is a clinical-stage company with no approved products and no historical revenue, Inventiva has incurred significant losses since its inception, Inventiva has never generated revenue from product sales, Inventiva will need additional capital to fund its operations, without which Inventiva may be required to significantly reduce its activities, delay or discontinue one or more of its research or development programs, expand its activities or capitalize on its business opportunities, and may not be able to continue as a going concern. Inventiva's ability to obtain financing and complete potential transactions on a timely basis, as well as whether, when, and to what extent dilutive instruments may be exercised and by which holders, Inventiva's future success depends on the successful clinical development, regulatory approvals, and subsequent commercialization of lanifibranor, preclinical studies or previous clinical trials are not necessarily predictive of future results, and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' claims regarding product candidates, Inventiva's expectations regarding its clinical trials may prove to be incorrect, and regulatory authorities may require additional stops and/or modifications to Inventiva's clinical trials. Inventiva's expectations regarding the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to implement its commercialization, marketing, and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with its existing partners or enter into new partnerships, and to fulfil its obligations under any agreements entered into in connection with such partnerships, the benefits of its current and future partnerships on the clinical development, regulatory approvals, and, if applicable, commercialization of its product candidates, as well as the achievement of milestones and timelines anticipated in connection with such partnerships, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of the applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, the recruitment and retention of patients in clinical trials is a costly and time-consuming process that could be made more difficult or impossible by multiple factors beyond the control of Inventiva and its partners, Inventiva's product candidates may cause adverse reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces significant competition, and Inventiva's activities, preclinical studies, and clinical development programs, as well as timelines, Inventiva's financial condition and results of operations could be materially and adversely affected by changes in laws and regulations, adverse conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and the resulting sanctions, the conflict in the Middle East and the related risk of a wider conflict and ongoing conflicts, epidemics, and macroeconomic conditions, including changes in international trade policies, global inflation, fluctuations in financial and credit markets, customs duties and other trade barriers, political unrest and natural disasters, uncertain financial markets, and disruptions in banking systems. In light of these risks and uncertainties, no representation is made as to the accuracy or completeness of these forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts, and estimates are only valid as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements.
Veuillez vous référer au Document d'Enregistrement Universel pour l'exercice clos le 31 décembre 2025 déposé auprès de l'Autorité des Marchés Financiers le 8 avril 2026, au Rapport Annuel sur le Formulaire 20-F pour l'exercice clos le 31 décembre 2025 déposé auprès de la Securities and Exchange Commission (la << SEC >>) le 8 avril 2026 pour d'autres risques et incertitudes affectant Inventiva, y compris ceux susceptibles de mettre en cause la continuité d'exploitation, et ceux décrits sous la rubrique << Facteurs de risques >>, et dans les futurs dépôts auprès de la SEC. D'autres risques et incertitudes dont Inventiva n'est pas actuellement consciente peuvent également affecter ses déclarations prospectives et peuvent faire en sorte que les résultats réels et le calendrier des événements diffèrent matériellement de ceux anticipés. Toutes les informations contenues dans ce communiqué de presse sont à jour à la date du communiqué. Sauf obligation légale, Inventiva n'a ni l'intention ni
l'obligation de mettre à jour ou de réviser les déclarations prospectives mentionnées ci-dessus. Par conséquent, Inventiva n'accepte aucune responsabilité pour les conséquences découlant de l'utilisation de l'une des déclarations susmentionnées.
Attachment
-- Inventiva - EN - Results of the votes of the shareholder meeting - PR -
06 30 2026
(END) Dow Jones Newswires
July 02, 2026 16:00 ET
Comments